Literature DB >> 10501231

Enhancement of DNA vaccine potency using conventional aluminum adjuvants.

J B Ulmer1, C M DeWitt, M Chastain, A Friedman, J J Donnelly, W L McClements, M J Caulfield, K E Bohannon, D B Volkin, R K Evans.   

Abstract

The immunogenicity and protective efficacy of DNA vaccines have been amply demonstrated in numerous animal models of infectious disease. However, the feasibility of DNA vaccines for human use is not yet known. In order to investigate potential means of increasing the potency of DNA vaccines, conventional adjuvants such as aluminum salts were tested. Coadministration of these adjuvants with DNA vaccines substantially enhanced the ability of these vaccines to induce antibody responses up to 100-fold in mice and guinea pigs, and 5-10-fold in non-human primates. Effective formulations had no demonstrable effect on the levels of antigen expression in situ and consisted of adjuvants that did not form complexes with the plasmid DNA; rather they exerted their effects on antigen after expression in situ. Therefore, the potency of DNA vaccines both in laboratory rodents and in non-human primates can be substantially increased by simple formulation with conventional aluminum adjuvants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501231     DOI: 10.1016/s0264-410x(99)00151-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

Authors:  M Briones; M Singh; M Ugozzoli; J Kazzaz; S Klakamp; G Ott; D O'Hagan
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

3.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance.

Authors:  Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Jina Kazzaz; Elawati Soenawan; Derek T O'Hagan
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

Review 5.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

6.  Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.

Authors:  Ingrid Karlsson; Marie Borggren; Jens Nielsen; Dennis Christensen; Jim Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2017-06-14       Impact factor: 3.452

7.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

8.  Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response.

Authors:  Marcin Kwissa; Erik B Lindblad; Reinhold Schirmbeck; Joerg Reimann
Journal:  J Mol Med (Berl)       Date:  2003-07-16       Impact factor: 4.599

9.  Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.

Authors:  D Marsac; D Loirat; C Petit; O Schwartz; M-L Michel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Authors:  Robert W Kaminski; K Ross Turbyfill; C Chao; W M Ching; Edwin V Oaks
Journal:  Clin Vaccine Immunol       Date:  2009-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.